The research team, led by Jizhong Cao of Huangshi Hospital of Traditional Chinese Medicine and Haiting Meng of Huangshi Second Hospital in China, set out to map the entire landscape of review-level evidence on digital respiratory management in young patients. Rather than running yet another meta-analysis, they conducted what methodologists call an overview of systematic reviews — a study of studies of studies — designed to identify which clinical conclusions are actually supported and where critical uncertainties remain.

The team searched four major databases — PubMed, Embase, the Cochrane Library and CINAHL — from their inception to 8 June 2026, hunting for systematic reviews of digital respiratory management or rehabilitation in people aged 18 or younger. When reviews included mixed populations, the researchers extracted only pediatric respiratory findings that could be separately identified. They then assessed the methodological quality of each review using two complementary tools: ROBIS, which gauges risk of bias in systematic reviews, and AMSTAR 2, which rates overall confidence in review findings.

Crucially, the team also tackled a problem that plagues this literature: overlap. When multiple systematic reviews recycle the same primary trials, the evidence base looks bigger than it really is. To quantify this, the researchers calculated the corrected covered area, or CCA, a statistical measure of how much the included studies overlap across reviews. They consolidated linked primary reports and synthesized findings by disease, study design and outcome — without performing a new meta-analysis or fresh GRADE assessments.

The results were sobering. Fifteen systematic reviews contributed 83 distinct study units linked through 143 review–study connections, with a corrected covered area of just 5.16 percent — meaning the reviews, while numerous, drew on a relatively small pool of unique research. Asthma dominated the field, accounting for 69 of the 83 studies. Cystic fibrosis contributed 12 studies, while non-CF bronchiectasis and primary ciliary dyskinesia — conditions where digital tools might plausibly help — were represented by a single study each.

Quality assessments were equally revealing. ROBIS classified eight reviews as low risk of bias, five as high risk and two as unclear. AMSTAR 2 was harsher: only one review earned a rating of low confidence, while the remaining 14 were judged critically low confidence. In other words, the evidence base that clinicians might consult when deciding whether to recommend an app or telemedicine program rests largely on reviews with substantial methodological weaknesses.

The asthma findings themselves were contradictory. One pediatric-focused meta-analysis found no clear benefit of digital interventions on asthma control, with a standardized mean difference of 0.04 and a 95 percent confidence interval spanning −0.20 to 0.28 — an interval that crosses zero and therefore provides no statistically convincing effect. Another review, by contrast, reported improved asthma control, but with substantial heterogeneity across studies, meaning the underlying trials differed so much in populations, interventions and measures that pooling them obscures more than it reveals. Pediatric quality-of-life syntheses showed no clear advantage for digital approaches either.

The cystic fibrosis picture was even thinner. The available evidence consisted mainly of small, short-term exercise studies and feasibility reports — pilot work testing whether digital rehabilitation is practical, not rigorous trials demonstrating that it improves long-term health. And across all conditions, two domains stood out as dangerously underexplored: safety and cost-effectiveness. The reviewers found that adverse events and economic outcomes were insufficiently characterized in the existing literature, leaving clinicians and health systems without the information needed to weigh digital tools against conventional care.

The authors’ conclusion is blunt: current review evidence is insufficient to support routine addition of digital interventions across pediatric respiratory care. Some asthma outcomes appear favorable, but effects vary depending on the specific intervention and the outcome measured. Cystic fibrosis evidence is limited, and other pediatric respiratory conditions remain essentially evidence gaps. Overlap between reviews, methodological limitations and incomplete safety and economic data preclude firm practice recommendations.

What the field needs, the researchers argue, are adequately powered multicentre trials with long-term follow-up that capture clinical, safety and economic outcomes together. Until such trials arrive, the digital health revolution in pediatric respiratory medicine remains a promising hypothesis rather than an established practice — a reminder that in medicine, as elsewhere, more apps do not automatically mean more evidence. The review was registered with PROSPERO (CRD420261416488) and funded by the Natural Science Foundation of Hubei Province, with the funder having no role in the design, analysis or decision to publish.

Subject of Research: Evidence quality and overlap of digital health interventions for pediatric respiratory diseases

Article Title: Digital health interventions for children and adolescents with respiratory diseases: an overview of systematic reviews

Article References: Digital health interventions for children and adolescents with respiratory diseases: an overview of systematic reviews. (n.d.). https://doi.org/10.1186/s12887-026-07869-1

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07869-1

Keywords: digital health, pediatrics, respiratory disease, asthma, cystic fibrosis, telemedicine, systematic review, evidence quality, mHealth, children, health technology, Digital